HCC - Hepatocellular Carcinoma Clinical Trials

28 recruiting

HCC - Hepatocellular Carcinoma Trials at a Glance

28 actively recruiting trials for hcc - hepatocellular carcinoma are listed on ClinicalTrialsFinder across 6 cities in 9 countries. The largest study group is Phase 2 with 11 trials, with the heaviest enrollment activity in Shanghai, Bologna, and Hong Kong. Lead sponsors running hcc - hepatocellular carcinoma studies include IRCCS Azienda Ospedaliero-Universitaria di Bologna, Chinese University of Hong Kong, and Chang Gung Memorial Hospital.

Browse hcc - hepatocellular carcinoma trials by phase

Treatments under study

About HCC - Hepatocellular Carcinoma Clinical Trials

Looking for clinical trials for HCC - Hepatocellular Carcinoma? There are currently 28 studies actively recruiting participants. Clinical trials offer access to new treatments before they are widely available, and every approved therapy in use today was first tested through a clinical trial.

Below you can browse trials, sign up for alerts when new HCC - Hepatocellular Carcinoma trials open, and view eligibility criteria for each study. Each listing includes the study phase, locations, and enrollment details.

Frequently Asked Questions

Common questions about HCC - Hepatocellular Carcinoma clinical trials

A clinical trial is a carefully designed research study that tests new medical treatments, drugs, devices, or approaches in human volunteers. Every approved medication and treatment available today was proven safe and effective through clinical trials.

All clinical trials are reviewed and approved by Institutional Review Boards (IRBs) — independent committees that evaluate patient safety. Trials follow strict protocols, and your health is monitored closely throughout. You can withdraw at any time.

Not necessarily. Many trials compare the new treatment against the current standard of care, meaning all participants receive active treatment. When placebos are used, they are typically combined with standard treatment, not given alone. The trial description will always specify the design.

Under the Affordable Care Act, most private insurers are required to cover routine patient care costs during a clinical trial. The sponsor typically covers the investigational treatment itself. Medicare also covers routine costs for qualifying trials.

Yes. Participation is completely voluntary. You can withdraw at any time, for any reason, without it affecting your access to standard medical care.

Each trial has specific eligibility criteria — including age, diagnosis, disease stage, prior treatments, and general health. Browse the trials listed above and check their eligibility sections. You can also contact the trial site directly to discuss your situation.

Showing 120 of 28 trials

Recruiting
Phase 2

Ipilimumab N01 Combined With Sintilimab, Bevacizumab Biosimilar, and Hepatic Arterial Infusion Chemotherapy as Conversion Therapy for Unresectable Intermediate-Advanced Hepatocellular Carcinoma

HCC - Hepatocellular CarcinomaConversion Therapy
Tianjin Medical University Cancer Institute and Hospital43 enrolled1 locationNCT07560488
Recruiting
Phase 2

A Phase IIa, Single-arm, Open-label Clinical Study to Evaluate the Efficacy, Safety and PK of CVM-1118 in Combination With Sintilimab and TACE in Participants With Incurable/Non-metastatic HCC

HCC - Hepatocellular Carcinoma
TaiRx, Inc.40 enrolled1 locationNCT07521852
Recruiting

A Multicenter Prospective Study on the Performance of Spectral CT for Evaluating Treatment Response After TACE in Hepatocellular Carcinoma

HCC - Hepatocellular CarcinomaCTTACE(Transcatheter Arterial Chemoembolization)
Zhongda Hospital250 enrolled1 locationNCT07351669
Recruiting

Impact of Radiotherapy on ctDNA in Patients With Hepatocellular Carcinoma

HCC - Hepatocellular Carcinoma
Chinese University of Hong Kong15 enrolled1 locationNCT06885879
Recruiting
Phase 1

A Phase 1 Study of TGI-5 as Monotherapy and in Combination With Nivolumab in Subjects With Locally Advanced/Metastatic Solid Tumors

Melanoma (Skin Cancer)NSCLC (Non-small Cell Lung Cancer)CRC (Colorectal Cancer)+1 more
Hefei TG ImmunoPharma Co., Ltd.194 enrolled1 locationNCT07376707
Recruiting
Early Phase 1

Universal CAR-T Cells (REVO-UWD-03) for Advanced Hepatocellular Carcinoma and Lung Cancer

NSCLC (Advanced Non-small Cell Lung Cancer)HCC - Hepatocellular Carcinoma
Wondercel Biotech (ShenZhen)60 enrolled2 locationsNCT06653023
Recruiting
Not Applicable

Needle-based Percutaneous Ablation of Liver Tumors.

HCC - Hepatocellular CarcinomaLiver TumorsMetastatic Liver Tumor
inTumo Therapeutics, Inc.31 enrolled1 locationNCT06689670
Recruiting
Phase 2

Phase IIb Study of AST-3424 in Patients With AKR1C3-high Expressing Advanced Hepatocellular Carcinoma

HCC - Hepatocellular Carcinoma
Zhejiang Hisun Pharmaceutical Co. Ltd.75 enrolled1 locationNCT07310173
Recruiting
Not Applicable

Downstaging Unresectable Hepatocellular Carcinoma to Resectable Disease With Combined Immunotherapy and Stereotactic Beamed Radiotherapy: a Pilot Study

Unresectable Hepatocellular CarcinomaHCC - Hepatocellular Carcinoma
The University of Hong Kong30 enrolled1 locationNCT07305428
Recruiting
Phase 2Phase 3

The Efficacy of Sequential Treatment With Bevacizumab Combined With Atezolizumab in Advanced Liver Cancer With MASLD

HCC - Hepatocellular Carcinoma
Eastern Hepatobiliary Surgery Hospital20 enrolled1 locationNCT07285850
Recruiting
Phase 2

ICIs and Anti-VEGF Antibody/TKIs With or Without Interventional Therapy for Advanced HCC

HCC - Hepatocellular Carcinoma
Peking Union Medical College Hospital300 enrolled1 locationNCT07157969
Recruiting
Phase 1

A Study of GV20-0251 in Advanced or Refractory Solid Tumors

Endometrial CancerCholangiocarcinomaMelanoma+5 more
West China Hospital10 enrolled1 locationNCT07106827
Recruiting
Not Applicable

[68Ga]Ga-PSMA PET/CT in Hepatocellular Carcinoma: Impact of Multiparametric Dynamic Whole-body Imaging and Kinetic Modeling.

HCC - Hepatocellular Carcinoma
Nantes University Hospital40 enrolled2 locationsNCT06999837
Recruiting
Phase 2

Proton Radiotherapy Plus Tremelimumab/Durvalumab for BCLC Stage B and C HCC

HCC - Hepatocellular CarcinomaDurvalumabTremelimumab+1 more
Chang Gung Memorial Hospital45 enrolled1 locationNCT06999694
Recruiting

The Impact of Emotional Stress on Immunotherapy Outcomes in Liver Cancer Patients: A Multi-Cohort Study

Unresectable Hepatocellular CarcinomaPsychological DistressHCC - Hepatocellular Carcinoma+2 more
Guilin Medical University, China700 enrolled5 locationsNCT07141056
Recruiting
Phase 4

Efficacy & Safety of Anticoagulants in Cirrhosis ± HCC

CirrhosisHCC - Hepatocellular CarcinomaPortal Vein Thrombosis
Mansoura University100 enrolled1 locationNCT07132515
Recruiting
Phase 2

Fecal Microbiota Transfer in Liver Cancer to Overcome Resistance to Atezolizumab/Bevacizumab (FLORA)

ImmunotherapyHCC - Hepatocellular Carcinoma
Michael Dill48 enrolled7 locationsNCT05690048
Recruiting

Non-invasive Assessment for Outcome Prediction in Patients With Hepatocellular Carcinoma

CirrhosisHCC - Hepatocellular Carcinoma
Chinese University of Hong Kong159 enrolled1 locationNCT07036874
Recruiting
Phase 2

Photon Radiotherapy Plus Tremelimumab/Durvalumab for BCLC Stage B and C HCC

RadiotherapyHCC - Hepatocellular CarcinomaDurvalumab+1 more
Chang Gung Memorial Hospital45 enrolled1 locationNCT06999707
Recruiting
Not Applicable

ctDNA Monitoring in Patients With HCC and mCRC

Colorectal Cancer MetastaticHCC - Hepatocellular Carcinoma
Medical University of Warsaw300 enrolled1 locationNCT07001085